The Stablepharma Story

Decades of pioneering research by our founder, Dr. Bruce Roser, into the stabilising properties of trehalose culminated in the creation of StablevaX™—our patented technology platform that enables advanced pharmaceutical thermostabilisation. Trehalose is a disaccharide sugar known for its exceptional stabilising properties, particularly in biological systems, making it highly effective in preserving the potency and shelf-life of vaccines and lifesaving pharmaceuticals, especially those requiring cold-chain or ambient-temperature storage.

Our technology is simple – StablevaX™ reformulates vaccines and biologicals into thermostable products which are innovative, sustainable and offer a greatly enhanced shelf-life.

Our StablevaX™ Technology

StablevaX™: A Clinical Stage, GMP-Enabled Technology Platform

Proven Technology Platform Supported by Robust Clinical and Scientific Evidence

Stablepharma has generated significant clinical and scientific evidence, with results from our lead candidate vaccine SPVX02, intended as an adult booster for the prevention of tetanus and diphtheria infection, demonstrating maintained potency following exposure to temperatures up to 40°C+ for years and through multiple freeze-thaw cycles. This innovation improves dramatically on current standards which recommend vaccines are stored between 2°C–8°C and mRNA vaccines at -20°C.

If you are interested in learning more about our results, please get in touch: info@stablepharma.com.